BMS is celebrated for its innovations in treatments for cancer, HIV/AIDS, cardiovascular disease, and other serious illnesses. The company has a strong global presence with R&D and manufacturing sites across the U.S., Europe, and Asia. Strategic acquisitions such as Celgene have strengthened its portfolio, making BMS a major player in oncology and immunology. In 2022, the company reported revenues of $46.4 billion and continuously invests in cutting-edge therapies aimed at improving patient outcomes.
Asset class
Impact theme
Investment geographies
